MAXCYTE INC. - COMMON STOCK

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

10 апр 2024 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

02 апр 2024 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

12 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

04 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

09 фев 2024 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

30 янв 2024 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

23 янв 2024 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

08 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

03 янв 2024 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

02 янв 2024 02:00:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

11 дек 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

16 ноя 2023 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

08 ноя 2023 16:05:01 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Two Upcoming Investor Conferences

06 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

04 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

06 сен 2023 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte to Participate in Baird Global Healthcare Conference

05 сен 2023 08:05:00 Источник Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

09 авг 2023 16:05:01 Источник Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

01 авг 2023 08:05:51 Источник Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

13 июл 2023 08:05:00 Источник Nasdaq GlobeNewswire